European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision

To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

[1]  M. Lunn,et al.  Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  L. H. van den Berg,et al.  Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies , 2020, Journal of Neurology.

[3]  Sonia Pujol,et al.  An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study , 2020, Journal of the peripheral nervous system : JPNS.

[4]  N. van Alfen,et al.  Nerve ultrasound for diagnosing chronic inflammatory neuropathy , 2020, Neurology.

[5]  G. Marfia,et al.  Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy , 2020, Journal of Neuroimmunology.

[6]  G. Liberatore,et al.  Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. , 2020, Journal of the peripheral nervous system : JPNS.

[7]  T. Maisonobe,et al.  Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment , 2020, Journal of the peripheral nervous system : JPNS.

[8]  G. Marfia,et al.  Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: Data from the Italian CIDP database , 2020, Journal of the peripheral nervous system : JPNS.

[9]  J. Hendrikse,et al.  Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies , 2020, Muscle & nerve.

[10]  Wenying Wang,et al.  Sonographic measurements of normal C5‐C8 nerve roots in children , 2020, Muscle & nerve.

[11]  Y. Rajabally,et al.  Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy , 2020, Muscle & nerve.

[12]  L. H. van den Berg,et al.  Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies , 2020, Neurology.

[13]  S. Groeschel,et al.  Nerve ultrasound reference data in children from two to seven years , 2020, Clinical Neurophysiology.

[14]  P. Lozeron,et al.  Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy , 2020, European Journal of Neurology.

[15]  M. Caan,et al.  Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies , 2019, Neurology.

[16]  Stefano Tamburin,et al.  Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment , 2019, Journal of the peripheral nervous system : JPNS.

[17]  A. Argyriou,et al.  Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment , 2019, Journal of the peripheral nervous system : JPNS.

[18]  E. Naumova,et al.  Nerve ultrasound normal values in children and young adults , 2019, Muscle & nerve.

[19]  E. Meinl,et al.  Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[20]  Jeffrey A. Allen,et al.  Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis , 2019, Muscle & nerve.

[21]  H. Hartung,et al.  Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[22]  P. Sarrigiannis,et al.  Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis , 2019, Pain and Therapy.

[23]  A. J. van der Kooi,et al.  Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy , 2019, Journal of the peripheral nervous system : JPNS.

[24]  R. Rojas-García,et al.  Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy , 2019, Scientific Reports.

[25]  P. V. D. Van den Bergh,et al.  Compliance with international guidelines for chronic inflammatory neuropathies , 2019, European journal of neurology.

[26]  Y. Rajabally,et al.  Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy , 2018, Journal of Neurology.

[27]  P. Dyck,et al.  Expanded teased nerve fibre pathological conditions in disease association , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[28]  G. Marfia,et al.  Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[29]  L. H. van den Berg,et al.  Nerve ultrasound and magnetic resonance imaging in the diagnosis of neuropathy , 2018, Current opinion in neurology.

[30]  G. L. Masson,et al.  Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial , 2018, The Lancet Neurology.

[31]  E. Meinl,et al.  Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  S. Attarian,et al.  Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review , 2018, Muscle & nerve.

[33]  E. Meinl,et al.  Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance , 2018, Front. Immunol..

[34]  H. Schünemann,et al.  [GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[35]  R. Lewis,et al.  Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis , 2018, Muscle & nerve.

[36]  I. Illa,et al.  Head and voice tremor improving with immunotherapy in an anti‐NF155 positive CIDP patient , 2018, Annals of clinical and translational neurology.

[37]  G. L. Masson,et al.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial , 2018, The Lancet Neurology.

[38]  E. Brusse,et al.  Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy , 2017, Journal of the peripheral nervous system : JPNS.

[39]  Toshio Shimizu,et al.  Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein , 2017, Neurological Sciences.

[40]  L. H. van den Berg,et al.  A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy , 2017, European journal of neurology.

[41]  R. Gold,et al.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib , 2017, Journal of Neurology.

[42]  G. Bono,et al.  Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy , 2017, BMC Neurology.

[43]  N. Yuki,et al.  Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy , 2017, Brain : a journal of neurology.

[44]  T. Brannagan,et al.  Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy , 2017, Muscle & nerve.

[45]  G. Comi,et al.  Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases , 2017, Journal of Neurology.

[46]  D. Sherman,et al.  Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies , 2017, Neuromuscular Disorders.

[47]  H. Axer,et al.  Peripheral nerve ultrasound scoring systems: benchmarking and comparative analysis , 2017, Journal of Neurology.

[48]  R. Hughes,et al.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. , 2017, The Cochrane database of systematic reviews.

[49]  L. H. van den Berg,et al.  Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies , 2017, Neurology.

[50]  G. Guyatt,et al.  Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. , 2016, Journal of clinical epidemiology.

[51]  M. Lunn,et al.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. , 2016, The Cochrane database of systematic reviews.

[52]  H. Krämer,et al.  Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. , 2016, Brain : a journal of neurology.

[53]  R. Freeman,et al.  Pain in acquired inflammatory demyelinating polyneuropathies , 2016, Pain.

[54]  H. Hartung,et al.  Fampridine‐PR (prolonged released 4‐aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system , 2016, Journal of the peripheral nervous system : JPNS.

[55]  M. Reilly,et al.  A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies , 2016, Journal of the peripheral nervous system : JPNS.

[56]  S. Mazič,et al.  Adverse events in apheresis: An update of the WAA registry data. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[57]  C. Lacroix,et al.  Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinating polyneuropathies , 2016, Journal of the Neurological Sciences.

[58]  A. Steck,et al.  Anti‐TNF alpha medications and neuropathy , 2015, Journal of the peripheral nervous system : JPNS.

[59]  A. Schapira,et al.  Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces , 2015, European journal of neurology.

[60]  A. Hiwatashi,et al.  Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy , 2015, Annals of clinical and translational neurology.

[61]  R. Rojas-García,et al.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[62]  Toshio Shimizu,et al.  Effects of low frequency filtering on distal compound muscle action potential duration for diagnosis of CIDP: A Japanese–European multicenter prospective study , 2015, Clinical Neurophysiology.

[63]  T. Brannagan,et al.  Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies , 2015, Journal of clinical neuromuscular disease.

[64]  R. Lewis,et al.  CIDP diagnostic pitfalls and perception of treatment benefit , 2015, Neurology.

[65]  Jay Desai,et al.  Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions , 2015, Annals of Indian Academy of Neurology.

[66]  N. Yuki,et al.  Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. , 2015, Brain : a journal of neurology.

[67]  L. Richard,et al.  Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy - A Report of Three Cases , 2015, European Neurology.

[68]  N. Latov,et al.  Comparison of 2‐limb versus 3‐limb electrodiagnostic studies in the evaluation of chronic inflammatory demyelinating polyneuropathy , 2015, Muscle & nerve.

[69]  S. Dib-Hajj,et al.  Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  T. Suhara,et al.  Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy , 2015, Annals of Neurology.

[71]  Blair H. Smith,et al.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis , 2015, The Lancet Neurology.

[72]  M. Vermeulen,et al.  Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[73]  Stefano Tamburin,et al.  Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[74]  M. Reilly,et al.  CIDP: mimics and chameleons , 2014, Practical Neurology.

[75]  Y. Rajabally,et al.  Diagnostic value of MR imaging in the Lewis–Sumner syndrome: A case series , 2014, Journal of the Neurological Sciences.

[76]  T. Brannagan,et al.  Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy , 2014, Muscle & nerve.

[77]  Nuha M. Alkhawajah,et al.  Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients , 2014, Journal of Neurology.

[78]  I. N. van Schaik,et al.  Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern , 2014, BMC Neurology.

[79]  R. Blesa,et al.  Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg , 2014, Neurology.

[80]  T. Maisonobe,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[81]  A. Wåhlin,et al.  Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[82]  T. Maisonobe,et al.  Sensory chronic inflammatory demyelinating polyneuropathy: An under‐recognized entity? , 2013, Muscle & nerve.

[83]  A. Pestronk,et al.  Ultrasound of inherited vs. acquired demyelinating polyneuropathies , 2013, Journal of Neurology.

[84]  Kanta Tanaka,et al.  MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy: a single-institution, retrospective case–control study , 2013, BMJ Open.

[85]  W. Robberecht,et al.  Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) , 2013, Journal of the peripheral nervous system : JPNS.

[86]  Y. Rajabally,et al.  Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? , 2013, Journal of Neurology.

[87]  J. Jakobsen,et al.  Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy , 2013, European journal of neurology.

[88]  H. Hartung,et al.  Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG – the ICE study , 2013, European journal of neurology.

[89]  G. Nogales-Gadea,et al.  Antibodies to contactin‐1 in chronic inflammatory demyelinating polyneuropathy , 2013, Annals of neurology.

[90]  Stefano Tamburin,et al.  Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial , 2012, The Lancet Neurology.

[91]  A. V. van Norden,et al.  Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment , 2012, Neurology.

[92]  Y. Rajabally,et al.  Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. , 2012, Journal of clinical neuromuscular disease.

[93]  S. Kuwabara,et al.  Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[94]  L. Benedetti,et al.  Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis , 2011, European journal of neurology.

[95]  P. Dyck,et al.  Painless diabetic motor neuropathy: A variant of diabetic lumbosacral radiculoplexus Neuropathy? , 2011, Annals of neurology.

[96]  F. Bombelli,et al.  Non‐anti‐MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases , 2011, European journal of neurology.

[97]  M. Bakkers,et al.  Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies , 2011, Neurology.

[98]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[99]  C. Lacroix,et al.  Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies , 2010, Journal of the peripheral nervous system : JPNS.

[100]  T. Nurmikko,et al.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision , 2010, European journal of neurology.

[101]  R. Hughes,et al.  Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[102]  A. Schenone,et al.  Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[103]  A. Mahadevan,et al.  Sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy: are supportive pathologic criteria useful in diagnosis? , 2010, Neurology India.

[104]  H. Hartung,et al.  Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. , 2010, Archives of neurology.

[105]  W. Hop,et al.  Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[106]  B. Jacobs,et al.  Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome , 2010, Neurology.

[107]  A. V. van Norden,et al.  Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial , 2010, The Lancet Neurology.

[108]  P. Bergh,et al.  European Federation of Neurological Societies / Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision Members , 2010 .

[109]  T. Maisonobe,et al.  A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy , 2010, Journal of the peripheral nervous system : JPNS.

[110]  R. Hughes,et al.  Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy , 2010, Neurology.

[111]  K. Sharma,et al.  Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[112]  L. Benedetti,et al.  A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy , 2010, European journal of neurology.

[113]  A. Hahn,et al.  Clinical and electrophysiological parameters distinguishing acute‐onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy , 2010, Muscle & nerve.

[114]  P. Bouche,et al.  Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[115]  A. Coles,et al.  Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy , 2009, Journal of Neurology.

[116]  P. Fuhr,et al.  Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy , 2009, Journal of the peripheral nervous system : JPNS.

[117]  R. Rojas-García,et al.  Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient , 2009, Muscle & nerve.

[118]  L. Magder,et al.  Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy , 2009, Journal of the Neurological Sciences.

[119]  Justin E. West,et al.  A Modified Approach to Sural Nerve Biopsy: Minimizing Complications , 2009, Annals of plastic surgery.

[120]  M. Lucchetta,et al.  Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study , 2009, The Lancet Neurology.

[121]  J. A. Bragg,et al.  Sensory nerve conduction slowing is a specific marker for CIDP , 2008, Muscle & nerve.

[122]  H. Hartung,et al.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.

[123]  M. Golightly,et al.  High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients , 2007, Journal of Neuroimmunology.

[124]  Y. Rajabally,et al.  The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy , 2007, Clinical Neurophysiology.

[125]  D. Hilton,et al.  Complications following sural and peroneal nerve biopsies , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[126]  J. Lünemann,et al.  Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy , 2007, Neurology.

[127]  R. Weinstein,et al.  Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: A prospective pilot trial , 2007, Muscle & nerve.

[128]  M. Meek,et al.  Sural Nerve Donor-Site Morbidity: Thirty-Four Years of Follow-up , 2006, Annals of plastic surgery.

[129]  R. Hughes,et al.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy * , 2006, European journal of neurology.

[130]  J. Pollard,et al.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society , 2006, European journal of neurology.

[131]  R. Hughes,et al.  Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[132]  G. Koutsis,et al.  Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy , 2006, Muscle & nerve.

[133]  G. Stoll,et al.  Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP , 2005, Neurology.

[134]  R. Hughes,et al.  Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[135]  L. Zinman,et al.  A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[136]  S. Jacob,et al.  Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases , 2005, Journal of the peripheral nervous system : JPNS.

[137]  K. Hirata,et al.  Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[138]  P. V. van Doorn,et al.  Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations , 2005, Neurology.

[139]  E. Wijdicks,et al.  Chronic inflammatory demyelinating polyneuropathy and respiratory failure , 2005, Journal of Neurology.

[140]  A. Windebank,et al.  History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation , 2005, Journal of the peripheral nervous system : JPNS.

[141]  M. Benatar,et al.  Sural and radial sensory responses in healthy adults: Diagnostic implications for polyneuropathy , 2005, Muscle & nerve.

[142]  D. Gladstone,et al.  High‐dose cyclophosphamide results in long‐term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy , 2005, Journal of the peripheral nervous system : JPNS.

[143]  T. Hashimoto,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement , 2005, Muscle & nerve.

[144]  H. Morita,et al.  Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy , 2004, Journal of the Neurological Sciences.

[145]  A. Ropper,et al.  Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy , 2004, Neurology.

[146]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[147]  G. Mancardi,et al.  Mycophenolate mofetil in dysimmune neuropathies: A preliminary study , 2004, Muscle & nerve.

[148]  P. V. D. Van den Bergh,et al.  Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy , 2004, Muscle & nerve.

[149]  A. Hays,et al.  Etanercept (Enbrel®) therapy for chronic inflammatory demyelinating polyneuropathy , 2003, Journal of the Neurological Sciences.

[150]  J. Vallat,et al.  Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: Evaluation of eight cases , 2003, Muscle & nerve.

[151]  R. Hughes,et al.  Mycophenolate in treatment‐resistant inflammatory neuropathies , 2002, European journal of neurology.

[152]  R. Schwartzman,et al.  High-dose cyclophosphamide without stem-cell rescue for refractory CIDP , 2002, Neurology.

[153]  P. Schmitz,et al.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies , 2002, Journal of neurology, neurosurgery, and psychiatry.

[154]  A. Jeanjean,et al.  Massive peripheral nerve hypertrophy in a patient with multifocal upper limb demyelinating neuropathy (Lewis-Sumner syndrome). , 2001, Acta neurologica Belgica.

[155]  P. Tonali,et al.  Pure motor chronic inflammatory demyelinating polyneuropathy , 2001, Journal of Neurology.

[156]  W. Bradley,et al.  Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis , 2001, Journal of the Neurological Sciences.

[157]  M. Ryan,et al.  Childhood Chronic Inflammatory Demyelinating Polyneuropathy: Clinical Course And Long‐Term Outcome , 2001 .

[158]  G. Sobue,et al.  Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy , 2001, Journal of the Neurological Sciences.

[159]  J. Griffin,et al.  Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases , 2001, Neurology.

[160]  G. Badger,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. , 2000, Archives of neurology.

[161]  S. Oh,et al.  Multifocal inflammatory demyelinating neuropathy: A distinct clinical entity? , 2000, Neurology.

[162]  Merkies Is,et al.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. , 2000 .

[163]  G. Gronseth,et al.  Distal acquired demyelinating symmetric neuropathy , 2000, Neurology.

[164]  J. Thonnard,et al.  Chronic demyelinating hypertrophic brachial plexus neuropathy , 2000, Muscle & nerve.

[165]  H. Franssen,et al.  Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy , 2000, Muscle & nerve.

[166]  H. Franssen,et al.  Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: A long-term follow-up study , 1999, Journal of Neurology.

[167]  J. Mcleod,et al.  Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. , 1999, Brain : a journal of neurology.

[168]  B. Sharrack,et al.  Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy , 1999, Neurology.

[169]  D. Burns,et al.  Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis–Sumner syndrome , 1999, Muscle & nerve.

[170]  K. Toyka,et al.  Clinical outcome of sural nerve biopsy: a retrospective study , 1999, Journal of Neurology.

[171]  F. Chédru,et al.  Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy , 1999, Neurology.

[172]  B. Peilot,et al.  Positive effects of tacrolimus in a case of CIDP. , 1998, Transplantation proceedings.

[173]  R. F. Mayer,et al.  Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy , 1998, Neurology.

[174]  J. Mcleod,et al.  Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy , 1998, Muscle & nerve.

[175]  R. Sakakibara,et al.  Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy , 1998, Neurology.

[176]  D. Zochodne,et al.  A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients Surgical approach and the role of collateral sprouting , 1998, Neurology.

[177]  R. D. de Haan,et al.  Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[178]  J. Albers,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long‐term follow‐up, with comparison to adults , 1997, Muscle & nerve.

[179]  C Detrembleur,et al.  Assessment of hand function in a patient with chronic sensory demyelinating neuropathy , 1997, Neurology.

[180]  K. Eriksson,et al.  Persistent Postoperative Complaints After Whole Sural Nerve Biopsies in Diabetic and Non‐diabetic Subjects , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[181]  S. Kuwabara,et al.  Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy , 1997, Neurology.

[182]  C Chalk,et al.  Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. , 1996, Brain : a journal of neurology.

[183]  M. Vérin,et al.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[184]  D. Claus,et al.  Focal upper limb demyelinating neuropathy. , 1996, Brain : a journal of neurology.

[185]  T. Crawford,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[186]  J. Kaplan,et al.  Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy” , 1995, Muscle & nerve.

[187]  W. Litchy,et al.  A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy , 1994, Annals of neurology.

[188]  S. Boniface,et al.  Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[189]  J. Albers,et al.  Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy , 1993, Neurology.

[190]  J. Albers,et al.  Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders , 1993, Muscle & nerve.

[191]  S. Oh,et al.  "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[192]  W. Bradley,et al.  Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years , 1990, Acta neurologica Scandinavica.

[193]  J. Daube,et al.  Combined azathioprine and prednisone in chronic inflammatory‐demyelinating polyneuropathy , 1985, Neurology.

[194]  J. Albers,et al.  Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy , 1985, Muscle & nerve.

[195]  Mark J. Brown,et al.  Multifocal demyelinating neuropathy with persistent conduction block , 1982, Neurology.

[196]  R. Dinapoli,et al.  Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment , 1982, Annals of neurology.

[197]  J. Mcleod,et al.  Chronic relapsing polyneuritis , 1976, Journal of the Neurological Sciences.

[198]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[199]  J. Devaux,et al.  PERIPHERAL NEUROPATHIES: Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications , 2017 .

[200]  S. H. Sindrupb,et al.  Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy : randomized controlled trial study , 2016 .

[201]  H. Schünemann,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[202]  R. Barohn,et al.  Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders , 2014 .

[203]  R. D. de Haan,et al.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. , 2009, The Cochrane database of systematic reviews.

[204]  A. Verma.  Chronic Immune Sensory Polyradiculopathy: A Possibly Treatable Sensory Ataxia , 2006 .

[205]  J. Vallat,et al.  [Autonomic nervous system involvement in chronic inflammatory demyelinating polyneuropathy]. , 2005, Revue neurologique.

[206]  A. Ropper,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. , 1998, Neurology.

[207]  M. M. Kitakule,et al.  Massive nerve root hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. , 1997, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[208]  D. S. Kim,et al.  Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? , 1997, Journal of the peripheral nervous system : JPNS.

[209]  Quantifying Treatment-Related Fluctuations in CIDP Results of the GRIPPER Study , 2022 .